Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

被引：11
|
作者：
Joly, V
Moroni, M
Concia, E
Lazzarin, A
Hirschel, B
Jost, J
Chiodo, F
Bentwich, Z
Love, WC
Hawkins, DA
Wilkins, EGL
Gatell, AJ
Vetter, N
Greenwald, C
Freimuth, WW
De Cian, W
机构：
[1] Hop Bichat, Dept Internal Med, F-75877 Paris 18, France
[2] Osped L Sacco, Div Infect Dis, Milan, Italy
[3] Osped San Raffaele, Div Infect Dis, Milan, Italy
[4] Pharmacia & Upjohn Co, Milan, Italy
[5] Osped S Orsola Malpighi, Div Infect Dis, Bologna, Italy
[6] Osped Borgo Roma, Div Infect Dis, Verona, Italy
[7] Hop Cantonal Univ Geneva, Div Infect Dis, CH-1211 Geneva, Switzerland
[8] Universitatsspital Abt, Div Infect Dis, Zurich, Switzerland
[9] Kaplan Hosp, Clin Immunol, Rehovot, Israel
[10] Ruchill Hosp, Dept Infect & Trop Med, Glasgow G20 9NB, Lanark, Scotland
[11] Kolber Ctr, London, England
[12] N Manchester Grp Hosp, Dept Infect Dis, Manchester, Lancs, England
[13] Hosp Clin & Provencialo, Div Infect Dis, Barcelona, Spain
[14] Wiener Wald Pulm Zentrum Sanatorium, Dept Med, Vienna, Austria
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2000年 / 44卷 / 11期
关键词：
D O I：
10.1128/AAC.44.11.3155-3157.2000
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
引用
收藏
页码：3155 / 3157
页数：3
相关论文
共 50 条
  • [41] Beneficial Effects of a Combination of Korean Red Ginseng and Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Patients
    Sung, Heungsup
    Jung, You-Sun
    Cho, Young-Keol
    CLINICAL AND VACCINE IMMUNOLOGY, 2009, 16 (08) : 1127 - 1131
  • [42] Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years
    Zhou, Hua-Ying
    Zheng, Yu-Huang
    Zhang, Chun-Ying
    Chen, Jun
    He, Yan
    Ding, Pei-Pei
    Li, Hui
    VIRAL IMMUNOLOGY, 2007, 20 (01) : 180 - 187
  • [43] Accumulation of defective viral genomes in peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected individuals
    Sanchez, G
    Xu, XY
    Chermann, JC
    Hirsch, I
    JOURNAL OF VIROLOGY, 1997, 71 (03) : 2233 - 2240
  • [44] Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants
    Lennerstrand, J
    Hertogs, K
    Stammers, DK
    Larder, BA
    JOURNAL OF VIROLOGY, 2001, 75 (15) : 7202 - 7205
  • [45] Zidovudine treatment in patients with primary (Acute) human immunodeficiency virus type 1 infection: A randomized, double-blind, placebo-controlled trial
    Niu, MT
    Bethel, J
    Holodniy, M
    Standiford, HC
    Schnittman, SM
    JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (01): : 80 - 91
  • [46] Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
    Demeter, LM
    Shafer, RW
    Meehan, PM
    Holden-Wiltse, J
    Fischl, MA
    Freimuth, WW
    Para, MF
    Reichman, RC
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) : 794 - 797
  • [47] Herpes simplex virus infection of the central nervous system in human immunodeficiency virus-type 1-infected patients
    Grover, D
    Newsholme, W
    Brink, N
    Manji, H
    Miller, R
    INTERNATIONAL JOURNAL OF STD & AIDS, 2004, 15 (09) : 597 - 600
  • [48] Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: Relationships to host factors, cellular restoration, and virologic end points
    Wu, HL
    Kuritzkes, DR
    McClernon, DR
    Kessler, H
    Connick, E
    Landay, A
    Spear, G
    Heath-Chiozzi, M
    Rousseau, F
    Fox, L
    Spritzler, J
    Leonard, JM
    Lederman, MM
    JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (04): : 799 - 807
  • [49] Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients
    Goujard, C
    Vincent, I
    Meynard, JL
    Choudet, N
    Bollens, D
    Rousseau, C
    Demarles, D
    Gillotin, C
    Bidault, R
    Taburet, AM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) : 118 - 123
  • [50] Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1-infected patients, in immunocompromised Macaques
    Edghill-Smith, Y
    Venzon, D
    Karpova, T
    McNally, J
    Nacsa, J
    Tsai, WP
    Tryniszewska, E
    Moniuszko, M
    Manischewitz, J
    King, LR
    Snodgrass, SJ
    Parrish, J
    Markham, P
    Sowers, M
    Martin, D
    Lewis, MG
    Berzofsky, JA
    Belyakov, IM
    Moss, B
    Tartaglia, J
    Bray, M
    Hirsch, V
    Golding, H
    Franchini, G
    JOURNAL OF INFECTIOUS DISEASES, 2003, 188 (08): : 1181 - 1191
12345